5 minute read
Nov. 28, 2022

GDC-2394: an Oral NLRP3 Inflammasome Inhibitor

GDC-2394

oral NLRP3 inhibitor predicted human dose of 500 mg QD LLE opt. and tox. mitig. from prev. clin. Cand. J. Med. Chem. Genentech, South San Francisco, CA

twitterlinkedinprintemail